ALK and lung adenocarcinoma: Although the underlying mechanism of lung adenocarcinoma is still under investigation, studies showed that recurrent mutations in the epidermal growth factor receptor (EGFR) and the anaplastic lymphoma kinase (ALK) fusions could change the efficacy of treatment for patients with lung adenocarcinoma [4-8].